Celltrion Gets FDA Nod For Subcutaneous Infliximab
Zymfentra, Marketed Globally As Remsima SC, Receives Approval In US
Celltrion has received FDA approval for Zymfentra, its subcutaneous formulation of infliximab that is marketed in other global territories as Remsima SC.
You may also be interested in...
Generics Bulletin previews the most noteworthy and anticipated events for February 2024.
Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.